Limited Stage Small Cell Lung Cancer Clinical Trial
Official title:
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy: a Multicenter Randomized Controlled Phase III Clinical Trial
This is a prospective, open,multicenter, randomized controlled phase III clinical trial. In patients with LS-SCLC who achieve remission after first-line chemoradiotherapy, the efficacy and safety of PCI or MRI surveillance is evaluated and analyzed. PCI is performed in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. MRI surveillance alone (delaying radiation until the actual brain metastasis) may be not inferior to PCI.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
Recruiting |
NCT05443646 -
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
|
Phase 2 | |
Completed |
NCT00066742 -
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05034133 -
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
Recruiting |
NCT05942508 -
A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy
|
Phase 1 | |
Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05483543 -
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
|
Phase 2 | |
Active, not recruiting |
NCT02046733 -
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
|
Phase 2 | |
Completed |
NCT04952597 -
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05623267 -
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
|
Phase 2/Phase 3 | |
Completed |
NCT01457469 -
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06117774 -
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
|
Phase 3 | |
Completed |
NCT01999881 -
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
|
N/A | |
Not yet recruiting |
NCT05496166 -
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT00470054 -
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00084487 -
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06256237 -
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
|
Phase 2 |